FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309157098> ?p ?o ?g. }

• W4309157098 endingPage "217" @default.
• W4309157098 startingPage "197" @default.
• W4309157098 abstract "Increasing numbers of BReast CAncer (BRCA) 1 or 2 pathogenic variant (PV) carriers, who have an inherited predisposition to breast and ovarian cancer, are being identified. Among these women, data regarding the effects of contraception on cancer risks are unclear and various guidelines provide various recommendations.We aim to optimize counselling regarding contraception for BRCA1/2-PV carriers. Therefore, we performed a systematic review and meta-analysis. We investigated the risk ratio for developing breast cancer or ovarian cancer in BRCA1/2-PV carriers who have used any form of contraception versus non-users. Second, we analysed breast and ovarian cancer risk among BRCA1/2-PV carriers as influenced by the duration of contraceptive use and by the time since last use. In addition, we provide an overview of all relevant international guidelines regarding contraceptive use for BRCA1/2-PV carriers.A systematic search in the Medline database and Cochrane library identified studies describing breast and/or ovarian cancer risk in BRCA1/2-PV carriers as modified by contraception until June 2021. The search included medical subject headings, keywords and synonyms related to BRCA and contraceptives (any kind). PRISMA guidance was followed. Risk Of Bias In Non-randomized Studies of Interventions and Grading of Recommendations, Assessment, Development and Evaluations assessments were performed. Random-effects meta-analyses were used to estimate pooled effects for breast and ovarian cancer risk separately. Subgroup analyses were conducted for BRCA1 versus BRCA2 and for the various contraceptive methods.Results of the breast cancer risk with oral contraceptive pill (OCP) analysis depended on the outcome measure. Meta-analyses of seven studies with 7525 women revealed a hazard ratio (HR) of 1.55 (95% CI: 1.36-1.76) and of four studies including 9106 women resulted in an odds ratio (OR) of 1.06 (95% CI: 0.90-1.25), heterogeneity (I2) 0% and 52%, respectively. Breast cancer risk was still increased in ever-users compared with never-users >10 years after last OCP use. In contrast, ovarian cancer risk was decreased among OCP users: HR 0.62 (95% CI: 0.52-0.74) based on two studies including 10 981 women (I2: 0%), and OR 0.49 (95% CI: 0.38-0.63) based on eight studies including 10 390 women (I2: 64%). The protective effect vanished after cessation of use. Tubal ligation also protects against ovarian cancer: one study including 3319 women (I2: 0%): HR: 0.44 (95% CI: 0.26-0.74) and three studies with 7691 women (I2: 44%): OR: 0.74 (95% CI: 0.53-1.03). Data regarding other contraceptives were unavailable. No differences were observed between BRCA1 and BRCA2-PV carriers. The quality of evidence was either low or very low.The OCP potentially increases breast cancer risk, while ovarian cancer risk decreases with either the OCP and tubal ligation in BRCA1/2-PV carriers. Counselling of BRCA1/2-PV carriers should be personalized; the genetic and non-genetic factors (like prior risk-reducing surgeries, prior breast cancer and age) and patients' preferences (reversibility, ease of use, reliability and effect on menstrual cycle) should be balanced. To further optimize counselling for high-risk women, future research should focus on other (commonly used) contraceptive methods and cancer risks in this specific population, and on the potential impact of changing formulations over time." @default.
• W4309157098 created "2022-11-24" @default.
• W4309157098 creator A5016925494 @default.
• W4309157098 creator A5032965703 @default.
• W4309157098 creator A5049125742 @default.
• W4309157098 creator A5051213584 @default.
• W4309157098 creator A5071254697 @default.
• W4309157098 creator A5078762974 @default.
• W4309157098 creator A5086841102 @default.
• W4309157098 date "2022-11-16" @default.
• W4309157098 modified "2023-10-14" @default.
• W4309157098 title "Contraceptives and cancer risks in <i>BRCA1/2</i> pathogenic variant carriers: a systematic review and meta-analysis" @default.
• W4309157098 cites W1521030336 @default.
• W4309157098 cites W1527338770 @default.
• W4309157098 cites W1627728252 @default.
• W4309157098 cites W1966460562 @default.
• W4309157098 cites W1978585547 @default.
• W4309157098 cites W2006139714 @default.
• W4309157098 cites W2015837292 @default.
• W4309157098 cites W2018348449 @default.
• W4309157098 cites W2019067804 @default.
• W4309157098 cites W2026628573 @default.
• W4309157098 cites W2027138920 @default.
• W4309157098 cites W2040063892 @default.
• W4309157098 cites W2041634324 @default.
• W4309157098 cites W2046814345 @default.
• W4309157098 cites W2049476028 @default.
• W4309157098 cites W2052228611 @default.
• W4309157098 cites W2061635845 @default.
• W4309157098 cites W2073558289 @default.
• W4309157098 cites W2074667852 @default.
• W4309157098 cites W2085491990 @default.
• W4309157098 cites W2088114676 @default.
• W4309157098 cites W2088775813 @default.
• W4309157098 cites W2092253588 @default.
• W4309157098 cites W2097420679 @default.
• W4309157098 cites W2109887368 @default.
• W4309157098 cites W2110120517 @default.
• W4309157098 cites W2113098178 @default.
• W4309157098 cites W2119913499 @default.
• W4309157098 cites W2125435699 @default.
• W4309157098 cites W2147058464 @default.
• W4309157098 cites W2148976855 @default.
• W4309157098 cites W2149924819 @default.
• W4309157098 cites W2155216639 @default.
• W4309157098 cites W2156098321 @default.
• W4309157098 cites W2163324183 @default.
• W4309157098 cites W2164340315 @default.
• W4309157098 cites W2164994896 @default.
• W4309157098 cites W2165010366 @default.
• W4309157098 cites W2166187750 @default.
• W4309157098 cites W2166473248 @default.
• W4309157098 cites W2193160720 @default.
• W4309157098 cites W2338185498 @default.
• W4309157098 cites W2464924628 @default.
• W4309157098 cites W2477763233 @default.
• W4309157098 cites W2531269403 @default.
• W4309157098 cites W2556131601 @default.
• W4309157098 cites W2627871710 @default.
• W4309157098 cites W2766659061 @default.
• W4309157098 cites W2767122952 @default.
• W4309157098 cites W2775284533 @default.
• W4309157098 cites W2788589375 @default.
• W4309157098 cites W2911188335 @default.
• W4309157098 cites W2938903157 @default.
• W4309157098 cites W2944695242 @default.
• W4309157098 cites W2956423698 @default.
• W4309157098 cites W2972739160 @default.
• W4309157098 cites W2991792334 @default.
• W4309157098 cites W3003680672 @default.
• W4309157098 cites W3010350454 @default.
• W4309157098 cites W3018737314 @default.
• W4309157098 cites W3092364924 @default.
• W4309157098 cites W3095028302 @default.
• W4309157098 cites W3125522766 @default.
• W4309157098 cites W3132348352 @default.
• W4309157098 cites W3141455614 @default.
• W4309157098 cites W3188020638 @default.
• W4309157098 cites W4206034225 @default.
• W4309157098 cites W4206962449 @default.
• W4309157098 doi "https://doi.org/10.1093/humupd/dmac038" @default.
• W4309157098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36383189" @default.
• W4309157098 hasPublicationYear "2022" @default.
• W4309157098 type Work @default.
• W4309157098 citedByCount "1" @default.
• W4309157098 countsByYear W43091570982023 @default.
• W4309157098 crossrefType "journal-article" @default.
• W4309157098 hasAuthorship W4309157098A5016925494 @default.
• W4309157098 hasAuthorship W4309157098A5032965703 @default.
• W4309157098 hasAuthorship W4309157098A5049125742 @default.
• W4309157098 hasAuthorship W4309157098A5051213584 @default.
• W4309157098 hasAuthorship W4309157098A5071254697 @default.
• W4309157098 hasAuthorship W4309157098A5078762974 @default.
• W4309157098 hasAuthorship W4309157098A5086841102 @default.
• W4309157098 hasBestOaLocation W43091570981 @default.
• W4309157098 hasConcept C121608353 @default.
• W4309157098 hasConcept C126322002 @default.
• W4309157098 hasConcept C143998085 @default.

• next